StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)

Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –

Protalix BioTherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Protalix BioTherapeutics's operating income for the twelve months ending Jun 30, 2026 was $23.29M, up 183.1% year over year. For fiscal 2025 it was -$5.50M, down 240.4% from the year before. The highest annual figure on record is $10.46M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.50M-240.4%
FY2024Dec 31, 2024$3.92M-62.6%
FY2023Dec 31, 2023$10.46M–
FY2022Dec 31, 2022-$13.01M–
FY2021Dec 31, 2021-$20.46M-855.1%
FY2020Dec 31, 2020$2.71M–
FY2019Dec 31, 2019-$10.72M–
FY2018Dec 31, 2018-$19.31M–
FY2017Dec 31, 2017-$34.52M–
FY2016Dec 31, 2016-$33.16M–
FY2015Dec 31, 2015-$23.67M–
FY2014Dec 31, 2014-$28.56M–
FY2013Dec 31, 2013-$34.06M–
FY2012Dec 31, 2012-$12.17M–
FY2011Dec 31, 2011-$36.53M–
FY2010Dec 31, 2010-$29.97M–
FY2009Dec 31, 2009-$31.97M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.67M+298.6%
Q1 FY2026Mar 31, 2026$21.15M–
Q4 FY2025Dec 31, 2025-$4.66M-164.6%
Q3 FY2025Sep 30, 2025$2.13M-46.6%
Q2 FY2025Jun 30, 2025$1.17M–
Q1 FY2025Mar 31, 2025-$4.15M–
Q4 FY2024Dec 31, 2024$7.21M–
Q3 FY2024Sep 30, 2024$3.99M–
Q2 FY2024Jun 30, 2024-$2.43M-111.9%
Q1 FY2024Mar 31, 2024-$4.86M–
Q4 FY2023Dec 31, 2023-$5.62M–
Q3 FY2023Sep 30, 2023-$1.89M–
Q2 FY2023Jun 30, 2023$20.42M–
Q1 FY2023Mar 31, 2023-$2.46M–
Q4 FY2022Dec 31, 2022-$2.50M–
Q3 FY2022Sep 30, 2022-$3.13M–
Q2 FY2022Jun 30, 2022-$5.52M–
Q1 FY2022Mar 31, 2022-$1.87M–
Q4 FY2021Dec 31, 2021-$5.71M-301.0%
Q3 FY2021Sep 30, 2021-$1.89M-140.2%
Q2 FY2021Jun 30, 2021-$9.17M-516.6%
Q1 FY2021Mar 31, 2021-$3.71M–
Q4 FY2020Dec 31, 2020$2.84M–
Q1 FY2020Mar 31, 2020$4.69M–
Q4 FY2019Dec 31, 2019$2.20M–
Q3 FY2019Sep 30, 2019-$1.54M–
Q2 FY2019Jun 30, 2019-$5.84M–
Q1 FY2019Mar 31, 2019-$5.53M–
Q4 FY2018Dec 31, 2018-$3.67M–
Q3 FY2018Sep 30, 2018-$3.74M–
Q2 FY2018Jun 30, 2018-$6.74M–
Q1 FY2018Mar 31, 2018-$5.15M–
Q4 FY2017Dec 31, 2017-$9.58M–
Q3 FY2017Sep 30, 2017-$7.77M–
Q2 FY2017Jun 30, 2017-$10.81M–
Q1 FY2017Mar 31, 2017-$6.37M–
Q4 FY2016Dec 31, 2016-$8.72M–
Q3 FY2016Sep 30, 2016-$6.65M–
Q2 FY2016Jun 30, 2016-$9.93M–

More Protalix BioTherapeutics figures

See a number that looks wrong?